Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

HCV Testing Certification

2 May 2012 07:00

RNS Number : 5067C
BATM Advanced Communications Ld
02 May 2012
 



2 May 2012

 

BATM Advanced Communications Limited

CE certification for HCV (Hepatitis C) screening kit

 

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is pleased to announce that its wholly owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its HCV (Hepatitis C) Screening Kit.

 

The kit is a fourth generation Enzyme Immunoassay (Elisa) kit for the determination of antibodies to Hepatitis's C virus in human plasma or serum. Testing in external, independent labs has shown performance results of 100% for diagnostic sensitivity and 99.5% for diagnostic specificity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnoses and that laboratories are spared the significant and needless expense of repeat testing.

 

The kit enables two different method protocols, one especially developed for the Chinese market and a shorter version for the rest of the world.

 

This certification follows the Company's announcement of 23 March 2012 that it had received CE certification for its Detect 4 HIV Total Screening Kit.

 

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

 

Dr Zvi Marom, Chief Executive, of BATM commented:

"We're delighted to have received certification for the HCV screening kit which comes just after the clearance for our HIV kit. This is further evidence of the momentum that we are building within our medical division as we continue to add to our portfolio of products."

 

 

- Ends -

 

For further information:

 

Enquiries

 

BATM Advanced Communications +972 9866 2527   

Ofer Bar-Ner, CFO

 

Newgate Threadneedle 020 7653 9850

Josh Royston / Graham Herring

 

finnCap 020 7220 0500

Marc Young / Brian Patient

 

Shore Capital 020 7408 4090 

Pascal Keane

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSAFLFFESEEI
Date   Source Headline
26th May 20267:00 amRNSBlock Listing Interim Review
21st Apr 20267:00 amRNSPublication of Annual Report
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 202612:00 pmRNSHolding(s) in Company
10th Feb 20267:00 amRNSSale of Non-core Business
3rd Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RBATM selected as FPT Israel cybersecurity partner
12th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20267:00 amRNSHolding(s) in Company
8th Jan 202611:00 amRNSTransaction in own shares and Total Voting Rights
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
10th Dec 202512:00 pmRNSAGM Result, Directorate Change & AMS Sale Update
1st Dec 20257:00 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSBlock Listing Interim Review
17th Nov 20257:00 amRNSNew Carrier Ethernet Order
5th Nov 20257:00 amRNSNotice of AGM and Directorate Changes
6th Oct 20257:00 amRNSSale of Diagnostics Distributor
26th Sep 20257:00 amRNSDirectorate Change
18th Aug 20257:00 amRNSInterim Results
4th Aug 20257:00 amRNSTotal Voting Rights
24th Jul 20257:00 amRNSSale of Non-Core Businesses and Notice of Results
23rd Jun 20257:00 amRNSDirectorate Change
27th May 20257:00 amRNSBlock Listing Interim Review
12th May 20257:00 amRNSOrder for ultra-high speed encryption development
6th May 20257:00 amRNS-RBATM unveils new brand identity
8th Apr 202511:00 amRNSAnnual Report Publication and AGM Update Statement
27th Mar 20257:00 amRNSNew strategic customer for Edgility in Brazil
17th Mar 20257:00 amRNSFull Year Results
5th Mar 20257:00 amRNSUpdate on Strategy and Trading
24th Feb 20257:00 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSADOR appoints Nadhim Zahawi to lead Advisory Board
19th Dec 20243:30 pmRNSResult of AGM and Director Appointment
19th Dec 20247:00 amRNSNew Tier 1 Customer for Edgility in Mexico
11th Dec 20247:00 amRNSNATlab commences pre-clinical validation
3rd Dec 20247:00 amRNSBlock Listing Interim Review
2nd Dec 20247:00 amRNSBATM receives orders of $2.4m for Edgility
25th Nov 20247:00 amRNSBlock listing Interim Review
14th Nov 202411:00 amRNSNotice of AGM and Proposed Director Appointment
4th Nov 20247:00 amRNSTotal Voting Rights
19th Aug 20247:00 amRNSInterim Results
10th Jul 20247:00 amRNSAmazon Web Services partnership for Edgility
2nd Jul 20247:00 amRNSCommercial markets cybersecurity partnership
3rd Jun 20247:00 amRNSBlock Listing Interim Review
28th May 20247:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.